Solventum Co. (NYSE:SOLV) Shares Bought by Commerce Bank

Commerce Bank raised its holdings in Solventum Co. (NYSE:SOLV) by 25.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,263 shares of the company’s stock after acquiring an additional 3,486 shares during the quarter. Commerce Bank’s holdings in Solventum were worth $1,204,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD acquired a new position in shares of Solventum during the 1st quarter worth $5,889,000. CWM LLC acquired a new position in shares of Solventum during the 2nd quarter worth $473,000. Great Valley Advisor Group Inc. acquired a new position in shares of Solventum during the 2nd quarter worth $493,000. First Horizon Advisors Inc. acquired a new position in Solventum in the 2nd quarter valued at about $58,000. Finally, Swedbank AB acquired a new position in Solventum in the 2nd quarter valued at about $4,711,000.

Solventum Stock Performance

SOLV opened at $70.81 on Monday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The business has a 50-day moving average of $70.53 and a two-hundred day moving average of $62.30. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05.

Analyst Ratings Changes

Several research analysts recently weighed in on SOLV shares. The Goldman Sachs Group boosted their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. Stifel Nicolaus started coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. Wolfe Research started coverage on shares of Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. Piper Sandler boosted their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Finally, Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.